Danaher Corporation $DHR Shares Bought by Turtle Creek Wealth Advisors LLC

Turtle Creek Wealth Advisors LLC increased its position in shares of Danaher Corporation (NYSE:DHR) by 348.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,689 shares of the conglomerate’s stock after purchasing an additional 10,635 shares during the quarter. Turtle Creek Wealth Advisors LLC’s holdings in Danaher were worth $3,033,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Mainsail Asset Management LLC purchased a new stake in shares of Danaher during the third quarter valued at approximately $2,380,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Danaher in the 3rd quarter valued at $659,000. Nvwm LLC raised its stake in shares of Danaher by 1,240.7% during the 3rd quarter. Nvwm LLC now owns 362 shares of the conglomerate’s stock worth $80,000 after purchasing an additional 335 shares during the period. Covenant Asset Management LLC increased its holdings in Danaher by 94.4% during the third quarter. Covenant Asset Management LLC now owns 5,176 shares of the conglomerate’s stock worth $1,147,000 after buying an additional 2,514 shares during the last quarter. Finally, KG Capital Management purchased a new stake in shares of Danaher during the 3rd quarter worth approximately $622,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock traded up $6.83 during midday trading on Thursday, reaching $231.52. 2,554,761 shares of the company’s stock traded hands, compared to its average volume of 4,447,386. The firm has a market capitalization of $162.76 billion, a PE ratio of 41.12, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a 50-day moving average price of $212.92 and a two-hundred day moving average price of $195.39. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the company posted $0.77 EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research reports. Barclays increased their price objective on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Royal Bank Of Canada increased their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. UBS Group assumed coverage on Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Finally, Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Strategic NVIDIA collaboration: Danaher and NVIDIA are combining NVIDIA’s accelerated-computing and AI technologies with Danaher’s scientific instruments, laboratory automation, workflow software and life-sciences expertise. The initiative is intended to advance autonomous science and accelerate drug discovery and other laboratory research, potentially supporting long-term growth in Danaher’s life-sciences businesses. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: AI-powered laboratory expansion: Danaher reportedly plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations targeted for early 2027. Although the announcement had limited immediate market impact, it reinforces the company’s positioning in laboratory automation and AI-enabled scientific workflows. How to Invest in AI Drug Discovery
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong earnings-surprise history and currently has favorable Earnings ESP and consensus-estimate factors for its next quarterly report. Analysts expect earnings growth, which may support sentiment ahead of the results. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Upcoming earnings remain the key catalyst: Danaher is projected to announce quarterly results on Wednesday. The current reports point to a possible beat, but they do not provide new reported financial results; the stock’s next move will depend on actual revenue, earnings and forward guidance. Danaher Projected to Announce Earnings

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.